Teva Pharmaceutical Cash Flow - Quarterly (NYSE:TEVA)

Add to My Stocks
$17.6 $0.08 (0.45%) TEVA stock closing price Mar 21, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like Teva Pharmaceutical needs to disclose. The profit-loss statement shows Teva Pharmaceutical profits, the balance sheet shows Teva Pharmaceutical debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. This statement can tell if a company is running out of money while still being profitable and is useful in Teva Pharmaceutical stock analysis. Teva Pharmaceutical had a negative net income cash flow of $-4.72B till this quarter of 2017 Q3. This report is very useful in measuring the short term viability of a company. The cash from operating activities for Teva Pharmaceutical is $ 2017 Q3, which saw an increase from previous quarter.

View and download details of Teva Pharmaceutical cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q3
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.58B1.06B480M1.52B1.19B615M305M1.31B973M
Net Increase (Decrease) in Assets Liabilities-755M-711M-463M1.22B1.1B53M189M967M703M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net6.22B6.19B-188M2.17B223M796M249M1.67B1.15B
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment1B1.09B1.21B1.1B1.23B-308M-170M-248M-16M
Acquisition Disposition of Subsidiaires43M---36.15B-35.87B-2.31B-2.24B-3.31B-3.3B
Increase (Decrease) in Investments-194M-14M-6M-481M-316M-37M-29M-2B-1.93B
Other Cash Inflow (Outflow) from Investment Activities-277M-286M-22M-212M15M15M18M-5M-26M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares---364M363M349M342M3.24B-100M
Issuance (Repayment) of Debt Securities-498M-62M-24.58B25.53B284M285M2.87B-329M
Increase (Decrease) in Bank & Other Borrowings-1.63B-1.48B-1.35B2B1.32B758M38M29M1.55B
Payment of Dividends & Other Cash Distributions-1.01B-821M-411M-1.56B-1.15B-743M-367M-1.16B-865M
Other Cash from (used by) Financing Activities-107M-59M-7M-169M-143M-102M-31M-178M-164M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash36M29M28M-660M-164M-205M-208M-62M-43M
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year6.95B2.23B1.04B2.88B1.1B1.25B2B1.85B1.49B
Cash & Equivalents at Year End680M599M900M988M1.56B6.98B5.96B6.95B928M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Teva Pharmaceutical stock price history provides insight into historical stock price fluctuations, and Teva Pharmaceutical stock comparison chart enables peer comparison. Some of the key terms used in the statement of cash flows are:

  • Teva Pharmaceutical saw a positive change in Net Change in Cash and Cash Equivalents of $-308M till 2017 Q3. Apart from the Teva Pharmaceutical stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Teva Pharmaceutical increased its cash from operating activities to $2.33B till 2017 Q3. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $572M for TEVA till last quarter 2017 Q3 report.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-3.24B for Teva Pharmaceutical. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Teva Pharmaceutical Cash Flow

FCF margin

Quarterly Cash Flow Statements For Teva Pharmaceutical Industries Ltd (ADR) Peers

Allergan cash flow, Astrazeneca cash flow, Eagle Pharma cash flow, Fortress Biotech cash flow, Mylan cash flow